Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Bought by Gables Capital Management Inc.

Gables Capital Management Inc. increased its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRXFree Report) by 0.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 434,260 shares of the biopharmaceutical company’s stock after acquiring an additional 2,305 shares during the quarter. Catalyst Pharmaceuticals makes up 4.5% of Gables Capital Management Inc.’s portfolio, making the stock its 3rd biggest position. Gables Capital Management Inc.’s holdings in Catalyst Pharmaceuticals were worth $7,300,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the business. Boston Partners lifted its holdings in Catalyst Pharmaceuticals by 965.2% during the 4th quarter. Boston Partners now owns 1,541,660 shares of the biopharmaceutical company’s stock worth $25,610,000 after buying an additional 1,396,930 shares during the last quarter. Jupiter Asset Management Ltd. raised its stake in Catalyst Pharmaceuticals by 64.0% during the third quarter. Jupiter Asset Management Ltd. now owns 897,046 shares of the biopharmaceutical company’s stock worth $10,486,000 after acquiring an additional 350,184 shares during the period. Kennedy Capital Management LLC lifted its holdings in Catalyst Pharmaceuticals by 110.2% in the third quarter. Kennedy Capital Management LLC now owns 636,366 shares of the biopharmaceutical company’s stock worth $7,439,000 after acquiring an additional 333,562 shares during the last quarter. LSV Asset Management grew its holdings in shares of Catalyst Pharmaceuticals by 25.6% during the third quarter. LSV Asset Management now owns 1,240,769 shares of the biopharmaceutical company’s stock valued at $14,505,000 after purchasing an additional 253,100 shares during the last quarter. Finally, Clark Estates Inc. NY bought a new stake in shares of Catalyst Pharmaceuticals in the 3rd quarter worth approximately $2,198,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ CPRX traded up $0.17 during mid-day trading on Wednesday, reaching $16.66. 1,161,126 shares of the company traded hands, compared to its average volume of 1,424,754. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $11.09 and a fifty-two week high of $17.50. The firm has a market cap of $1.97 billion, a PE ratio of 30.85, a price-to-earnings-growth ratio of 1.35 and a beta of 0.89. The stock has a fifty day simple moving average of $15.67 and a 200-day simple moving average of $14.86.

Catalyst Pharmaceuticals (NASDAQ:CPRXGet Free Report) last issued its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.04. The company had revenue of $110.57 million for the quarter, compared to analysts’ expectations of $105.78 million. Catalyst Pharmaceuticals had a return on equity of 25.08% and a net margin of 15.83%. As a group, analysts predict that Catalyst Pharmaceuticals, Inc. will post 1.81 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on CPRX shares. HC Wainwright upped their price objective on Catalyst Pharmaceuticals from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, May 10th. Oppenheimer reiterated an “outperform” rating and issued a $29.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Wednesday, March 27th. TheStreet upgraded shares of Catalyst Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Tuesday, March 12th. StockNews.com downgraded Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, May 10th. Finally, Bank of America assumed coverage on Catalyst Pharmaceuticals in a research report on Thursday, March 7th. They issued a “buy” rating and a $23.00 target price on the stock. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Catalyst Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $26.71.

Get Our Latest Stock Analysis on CPRX

Insiders Place Their Bets

In related news, insider Brian Elsbernd sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $16.44, for a total transaction of $411,000.00. Following the completion of the sale, the insider now directly owns 124,433 shares in the company, valued at $2,045,678.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 11.00% of the stock is owned by company insiders.

Catalyst Pharmaceuticals Profile

(Free Report)

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

See Also

Want to see what other hedge funds are holding CPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRXFree Report).

Institutional Ownership by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.